Medicine Development

The research-based pharmaceutical industry is uniquely able to discover, develop, and produce lifesaving medicines for patients. To make the best use of our R&D investment and provide the greatest benefit to patients, we largely concentrate in therapeutic areas in which we have deep expertise, including diabetes, neuroscience, cardiovascular diseases, and oncology. We seek to develop pharmaceuticals that are "first-in-class" (i.e., creating a treatment where none existed) and/or "best-in-class" (i.e., improving on existing treatments). Here is how the process unfolds in the United States[1].

Lilly has a rich history of creating breakthrough products that enhance and preserve life. Today, our commitment to scientific research and development remains as strong as ever, and we've developed some innovative approaches that are helping us speed the creation of new medicines. Yet we recognize that the responsibilities we have go far beyond the laboratory.

[1] We have adapted the phase chart from PhRMA and supplemented it with cost data from a recently published article on R&D productivity: Paul S, Mytelka D, Dunwiddie C, et al. How to Improve R&D Productivity: The Pharmaceutical Industry's Grand Challenge . Nature Reviews Drug Discovery. 2010; available from: doi:10.1038/nrd3078. Accessed October 25, 2011.